Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies

NCT03555955 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT03555955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03555955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
November 20, 2018
Completion date
May 26, 2021
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, hematologic malignancy, myelodysplastic syndromes